Literature DB >> 19394990

Improved awareness of Pap smear may not affect its use in Nigeria: a case study of female medical practitioners in Enugu, southeastern Nigeria.

Cyril C Dim1, Esther Ekwe, Theresa Madubuko, Ngozi R Dim, Hyginus U Ezegwui.   

Abstract

Improved awareness of Pap test by Nigerian women may not necessarily increase its use. This hypothesis was tested using female medical practitioners in Enugu state, Nigeria. They were expected to be advocates of disease screening and therefore should lead by example. All respondents were aware of the Pap smear but only 18% had used it. The mean frequency of Pap smear was 1.8+/-1.2 (range 1-5). Repeat Pap tests were observed only among respondents that had screened as routine. The majority (32%) of those who never screened for cervical cancer had no reason. There may be more to the use of Pap smear among women in Nigeria than its awareness.

Entities:  

Mesh:

Year:  2009        PMID: 19394990     DOI: 10.1016/j.trstmh.2009.03.020

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  11 in total

1.  Experiences and unmet needs of women undergoing Pap smear cervical cancer screening: impact on uptake of cervical cancer screening in south eastern Nigeria.

Authors:  Chibuike O Chigbu; Azubuike K Onyebuchi; Chuma C Egbuji; Eusebus C Ezugwu
Journal:  J Cancer Educ       Date:  2015-03       Impact factor: 2.037

2.  Demographic, knowledge, attitudinal, and accessibility factors associated with uptake of cervical cancer screening among women in a rural district of Tanzania: three public policy implications.

Authors:  Frida S Lyimo; Tanya N Beran
Journal:  BMC Public Health       Date:  2012-01-10       Impact factor: 3.295

3.  Awareness of HPV and cervical cancer prevention among Cameroonian healthcare workers.

Authors:  Catherine McCarey; David Pirek; Pierre Marie Tebeu; Michel Boulvain; Anderson Sama Doh; Patrick Petignat
Journal:  BMC Womens Health       Date:  2011-10-18       Impact factor: 2.809

4.  Cervical cancer screening in women referred to healthcare centres in Tabriz, Iran.

Authors:  Azizeh Farshbaf-Khalili; Hanieh Salehi-Pourmehr; Mahnaz Shahnazi; Sina Yaghoubi; Parvaneh Gahremani-Nasab
Journal:  Niger Med J       Date:  2015 Jan-Feb

Review 5.  Analysis of the Determinants of Low Cervical Cancer Screening Uptake Among Nigerian Women.

Authors:  Humphrey Nwobodo; Maryam Ba-Break
Journal:  J Public Health Afr       Date:  2015-08-17

6.  Knowledge of Cervical Cancer and the Uptake of the Papanicolaou Smear Test among Public Secondary School Teachers in Akwa Ibom State, Nigeria.

Authors:  Augustina Elochukwu Ijezie; Ofonime Effiong Johnson
Journal:  Niger Med J       Date:  2019-11-26

7.  Cervical cancer and pap smear awareness and utilization of pap smear test among Federal civil servants in North Central Nigeria.

Authors:  Hyacinth I Hyacinth; Oluwatoyosi A Adekeye; Joy N Ibeh; Tolulope Osoba
Journal:  PLoS One       Date:  2012-10-01       Impact factor: 3.240

Review 8.  Factors affecting compliance with clinical practice guidelines for pap smear screening among healthcare providers in africa: systematic review and meta-summary of 2045 individuals.

Authors:  Etienne Asonganyi; Meenakshi Vaghasia; Clarissa Rodrigues; Amruta Phadtare; Anne Ford; Ricardo Pietrobon; Julius Atashili; Catherine Lynch
Journal:  PLoS One       Date:  2013-09-12       Impact factor: 3.240

9.  Knowledge, attitude and practice about cancer of the uterine cervix among women living in Kinshasa, the Democratic Republic of Congo.

Authors:  Catherine Ali-Risasi; Paul Mulumba; Kristien Verdonck; Davy Vanden Broeck; Marleen Praet
Journal:  BMC Womens Health       Date:  2014-02-18       Impact factor: 2.809

Review 10.  Cervical cancer prevention and treatment research in Africa: a systematic review from a public health perspective.

Authors:  Sarah Finocchario-Kessler; Catherine Wexler; May Maloba; Natabhona Mabachi; Florence Ndikum-Moffor; Elizabeth Bukusi
Journal:  BMC Womens Health       Date:  2016-06-04       Impact factor: 2.809

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.